NCT04957914 is a Phase 1 clinical trial of Insulin Glargine in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company.

Who is sponsoring NCT04957914?

NCT04957914 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT04957914?

Interventions in NCT04957914: Insulin Glargine, LY3209590.

What condition does NCT04957914 study?

NCT04957914 studies Type 2 Diabetes Mellitus.

Is NCT04957914 still recruiting?

NCT04957914 is currently completed. Last updated 16 November 2022.

Last reviewed 2022-11-16 · How we verify

NCT04957914

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus

Completed Phase 1 Last updated 16 November 2022

What this trial tests

Phase 1 trial testing Insulin Glargine in Type 2 Diabetes Mellitus in 54 participants. Completed in 17 October 2022.

Timeline

14 July 2021

Primary endpoint
17 October 2022

17 October 2022

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	basic science
Enrollment	54
Start date	14 July 2021
Primary completion	17 October 2022
Estimated completion	17 October 2022
Sites	1 location across Germany

Drugs / interventions tested

Insulin Glargine (INSULIN GLARGINE) — full drug profile →
LY3209590 — full drug profile →

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

Adults 18 to 70, any sex, with Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to evaluate the effect of study drug known as LY3209590 compared to insulin glargine administered in participants with type 2 diabetes mellitus (T2DM). Side effects and tolerability will be documented. The study will last almost six months and 21 visits for each participant including screening period.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa.
Rosenstock J, Juneja R, Beals JM, Moyers JS, et al · · 2024 · cited 51× · PMID 38224978 · DOI 10.1210/endrev/bnad037
Frequency and Severity of Hypoglycemia Under Conditions of Increased Hypoglycemic Risk with Insulin Efsitora Alfa Versus Insulin Glargine Treatment in Participants with Type 2 Diabetes.
Heise T, Andersen G, Pratt EJ, Leohr J, et al · · 2024 · cited 7× · PMID 38907935 · DOI 10.1007/s13300-024-01605-7

Verify or expand the search:

Other trials of Insulin Glargine

Trials testing the same drug.

NCT06370715 — A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India · Phase 4 · completed
NCT06178874 — Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia · NA · completed
NCT05803421 — A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and O · Phase 3 · completed
NCT05702073 — To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With · Phase 3 · completed
NCT05699408 — To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequate · Phase 3 · completed

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04957914 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 16 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04957914.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing